Header_cardiac

Medical Utility

  1. Prediction of risk of obesity, cardiovascular disease and breast cancer
  2. Prevention of disease by keeping pro-NT levels in a “low risk range”, e.g. by adapting nutritional habits or by life-style adjustments

sphingotest® pro-NT Immunoassay

  • Measures a stable fragment of the Neurotensin precursor Proneurotensin (pro-NT) that is produced in the same ratio as Neurotensin
  • The sphingotest® pro-NT Broschure can be downloaded here

Literature

 

  1. Li J, Song J, Zaytseva YY, Liu Y, Rychahou P, Jiang K, Starr ME, Kim JT, Harris JW, Yiannikouris FB, Katz WS, Nilsson PM, Orho-Melander M, Chen J, Zhu H, Fahrenholz T, Higashi RM, Gao T, Morris AJ, Cassis LA, Fan TW, Weiss HL, Dobner PR, Melander O, Jia J, Evers BM. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature. 2016; 533(7603):411-5. PubMed PMID: 27193687
  2. Ernst A, Hellmich S, Bergmann A. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation. Peptides. 2006; 27(7):1787-93. PubMed PMID: 16519961.
  3. Fawad A, Schultz C, Nilsson PM, Orho-Melander M, Melander O. 1C.07: Proneurotensin independently predicts cardiovascular disease. The Malmö Preventive Project. J Hypertens. 2015; 33 Suppl 1:e11. PubMed PMID: 26102676.
  4. Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engström G, Kilger U, Nilsson P, Bergmann A, Orho-Melander M. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012; 308(14):1469-75. PubMed PMID:23047361.
  5. Melander O, Belting M, Manjer J, Maisel AS, Hedblad B, Engström G, Nilsson P, Struck J, Hartmann O, Bergmann A, Orho-Melander M. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23(8):1672-6. PubMed PMID: 24925674.